Cardiac Fibrosis - Pipeline Review, H1 2014 @ http://www.researchmoz.us/cardiac-fibrosis-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Cardiac Fibrosis - Pipeline Review, H1 2014
Cardiac Fibrosis - Pipeline Review, H1 2014
Summary
Global Markets Directs, Cardiac Fibrosis - Pipeline Review, H1 2014, provides an overview of the Cardiac Fibrosiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cardiac Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cardiac Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cardiac Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 5
introduction 6
global Markets Direct Report Coverage 6
cardiac Fibrosis Overview 7
therapeutics Development 8
pipeline Products For Cardiac Fibrosis - Overview 8
pipeline Products For Cardiac Fibrosis - Comparative Analysis 9
cardiac Fibrosis - Therapeutics Under Development By Companies 10
cardiac Fibrosis - Therapeutics Under Investigation By Universities/institutes 12
cardiac Fibrosis - Pipeline Products Glance 13
clinical Stage Products 13
early Stage Products 14
Cardiac Fibrosis - Pipeline Review, H1 2014

2. unknown Stage Products 15
cardiac Fibrosis - Products Under Development By Companies 16
cardiac Fibrosis - Products Under Investigation By Universities/institutes 17
cardiac Fibrosis - Companies Involved In Therapeutics Development 18
merck & Co., Inc. 18
biolinerx, Ltd. 19
compugen Ltd. 20
digna Biotech, S.l. 21
promedior, Inc. 22
miragen Therapeutics, Inc. 23
fibrotech Therapeutics Pty. Ltd. 24
vida Therapeutics Inc. 25
ccrp Therapeutics Gmbh 26
cardiac Fibrosis - Therapeutics Assessment 27
assessment By Monotherapy Products 27
assessment By Target 28
assessment By Mechanism Of Action 31
assessment By Route Of Administration 34
assessment By Molecule Type 37
drug Profiles 39
card-024 - Drug Profile 39
product Description 39
mechanism Of Action 39
r&d Progress 39
p-17 - Drug Profile 41
product Description 41
mechanism Of Action 41
r&d Progress 41
disitertide - Drug Profile 42
product Description 42
mechanism Of Action 42
r&d Progress 42
cgen-856 - Drug Profile 44
product Description 44
mechanism Of Action 44
r&d Progress 44
prm-151 - Drug Profile 46
product Description 46
mechanism Of Action 46
r&d Progress 46
mgn-4220 - Drug Profile 48
product Description 48
mechanism Of Action 48
r&d Progress 48
pn1-ab - Drug Profile 49
product Description 49
mechanism Of Action 49
r&d Progress 49
ft-011 - Drug Profile 50
product Description 50
mechanism Of Action 50
r&d Progress 50
therapy For End-organ Damage - Drug Profile 51
product Description 51
mechanism Of Action 51
r&d Progress 51
tm-5441 - Drug Profile 52
product Description 52
mechanism Of Action 52
r&d Progress 52
cgen-856s - Drug Profile 53
product Description 53
mechanism Of Action 53
r&d Progress 53
drug For Fibrotic Diseases - Drug Profile 54
product Description 54
mechanism Of Action 54
r&d Progress 54
Cardiac Fibrosis - Pipeline Review, H1 2014

3. cyp11b2 Inhibitor Program - Drug Profile 55
product Description 55
mechanism Of Action 55
r&d Progress 55
cardiac Fibrosis - Recent Pipeline Updates 56
cardiac Fibrosis - Dormant Projects 60
appendix 61
methodology 61
coverage 61
secondary Research 61
primary Research 61
expert Panel Validation 61
contact Us 62
disclaimer 62
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Cardiac Fibrosis - Pipeline Review, H1 2014